RemeGen Co Ltd
688331
Company Profile
Business description
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
Contact
58 Middle Beijing Road
Yantai Area of Shandong Pilot Free Trade Zone
Yantai Development Zone
Yantai
CHNT: +86 5353573511
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3,070
Stocks News & Analysis
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.00 | 7.40 | -0.08% |
| CAC 40 | 7,674.78 | 24.14 | -0.31% |
| DAX 40 | 23,596.98 | 173.35 | -0.73% |
| Dow JONES (US) | 45,400.86 | 220.43 | -0.48% |
| FTSE 100 | 9,208.21 | 8.66 | -0.09% |
| HKSE | 25,486.94 | 68.96 | 0.27% |
| NASDAQ | 21,700.39 | 7.30 | -0.03% |
| Nikkei 225 | 43,669.26 | 650.51 | 1.51% |
| NZX 50 Index | 13,260.68 | 37.15 | 0.28% |
| S&P 500 | 6,481.50 | 20.58 | -0.32% |
| S&P/ASX 200 | 8,846.60 | 8.60 | -0.10% |
| SSE Composite Index | 3,818.82 | 6.31 | 0.17% |